Cannabidiol-hyaluronic acid combination delivered rectally for attenuating abacterial prostatitis symptoms: Single-arm open-label pilot clinical trial
Biomedical Papers · 2026
DOI: 10.5507/bp.2026.002 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Biomedical Papers, 2026. Verfasst von Vladimir Student und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Olomouc, Olomouc, Czech Republic. Hauptthemen laut MEDLINE: Prostatitis, Hyaluronic Acid, Cannabidiol. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent urological disorder with a significant impact on quality-of-life. This study assessed the effects of rectal administration of dual cannabidiol (CBD)/hyaluronic acid (HA)-based therapy in men with CP/CPPS. METHODS: A single-arm, open-label pilot trial on 16 men (24-49 years) with CP/CPPS (NIH Chronic Prostatitis Symptom Index [NIH-CPSI] >10, pain subscore ≥4). The participants self-administered rectal CANNEFF® suppositories containing CBD (100 mg) and HA (6.6 mg) as active ingredients, nightly for 30 days. Outcome measures included changes in NIH-CPSI total score, International Prostate Symptom Score (IPSS), and International Index of Erectile Function (IIEF-5). Safety and tolerability were also assessed. RESULTS: The median baseline NIH-CPSI score was 24.5 points (range 11, 39) decreasing to a median 20.0 (range 2, 26) at day 30 (P=0.003), with a median reduction of 7.0 points (range -20.0, 6.0). Symptom improvement was found in 81.3 % (13/16) of participants. The IPSS total score decreased from a median of 14.0 points (range 4, 32) to a median 12.0 (range 3, 18) (P=0.033), with voiding symptoms showing the largest improvement. The IIEF-5 score increased modestly but without statistical significance. No adverse events were reported. CONCLUSIONS: The administration of the suppositories with CBD/HA action demonstrated potential symptom relief in CP/CPPS with a favourable tolerability profile. A more nuanced analysis of NIH-CPSI changes and IPSS and IIEF-5 data suggests a clinically meaningful benefit for most participants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University Hospital Olomouc, Olomouc, Czech Republic.
- Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
- Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
Zitieren
APA
Student, V., Repa, V., Vrbkova, J., & Vacek, J. (2026). Cannabidiol-hyaluronic acid combination delivered rectally for attenuating abacterial prostatitis symptoms: Single-arm open-label pilot clinical trial. Biomedical Papers. https://doi.org/10.5507/bp.2026.002
Vancouver
Student V, Repa V, Vrbkova J, Vacek J. Cannabidiol-hyaluronic acid combination delivered rectally for attenuating abacterial prostatitis symptoms: Single-arm open-label pilot clinical trial. Biomedical Papers. 2026. doi:10.5507/bp.2026.002
BibTeX
@article{Student2026,
author = {Student, Vladimir and Repa, Vaclav and Vrbkova, Jana and Vacek, Jan},
title = {Cannabidiol-hyaluronic acid combination delivered rectally for attenuating abacterial prostatitis symptoms: Single-arm open-label pilot clinical trial},
journal = {Biomedical Papers},
year = {2026},
doi = {10.5507/bp.2026.002}
}
EUVIMED